MX2019001324A - Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel. - Google Patents
Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel.Info
- Publication number
- MX2019001324A MX2019001324A MX2019001324A MX2019001324A MX2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A MX 2019001324 A MX2019001324 A MX 2019001324A
- Authority
- MX
- Mexico
- Prior art keywords
- ocs
- skin
- treat inflammatory
- oxygenated cholesterol
- lesions
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 title abstract 2
- 206010040882 skin lesion Diseases 0.000 title abstract 2
- 231100000444 skin lesion Toxicity 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- -1 cholesterol sulfates Chemical class 0.000 title 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 abstract 1
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 abstract 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370036P | 2016-08-02 | 2016-08-02 | |
| US201762470576P | 2017-03-13 | 2017-03-13 | |
| PCT/US2017/044821 WO2018026767A1 (en) | 2016-08-02 | 2017-08-01 | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001324A true MX2019001324A (es) | 2019-07-04 |
Family
ID=61073120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001324A MX2019001324A (es) | 2016-08-02 | 2017-08-01 | Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190374554A1 (enExample) |
| EP (1) | EP3493671A4 (enExample) |
| JP (2) | JP2019524774A (enExample) |
| KR (2) | KR102568036B1 (enExample) |
| CN (1) | CN109862787A (enExample) |
| AU (2) | AU2017306140A1 (enExample) |
| BR (1) | BR112019001193A2 (enExample) |
| CA (1) | CA3031211A1 (enExample) |
| IL (1) | IL264389A (enExample) |
| MX (1) | MX2019001324A (enExample) |
| TW (2) | TW201818944A (enExample) |
| WO (1) | WO2018026767A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| SMT202200094T1 (it) | 2013-12-24 | 2022-05-12 | Univ Virginia Commonwealth | Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta |
| WO2018026781A1 (en) | 2016-08-02 | 2018-02-08 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| AU2021221109A1 (en) * | 2020-02-11 | 2022-08-25 | Durect Corporation | Treatment of infectious diseases |
| JP2023539595A (ja) * | 2020-08-26 | 2023-09-15 | オティカラ，インコーポレーテッド | 鼻、耳及び他の組織の感染症及び／又は炎症を処置するための組成物、デバイス及び方法 |
| CN113040140B (zh) * | 2021-01-28 | 2022-06-03 | 菲吉乐科(南京)生物科技有限公司 | 一种适合噬菌体浸入藤本和木本植物用的辅助渗透剂及其制备方法和应用 |
| CN113521094A (zh) * | 2021-05-23 | 2021-10-22 | 广州奇维生物信息技术有限公司 | 一种治疗湿疹的乳剂软膏及其制备方法 |
| CN114646702B (zh) * | 2022-03-03 | 2023-01-06 | 四川大学华西医院 | 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US20120253143A1 (en) * | 2011-04-04 | 2012-10-04 | Raphael Warren | Method of measuring a skin agent transferred to skin |
| WO2013154752A1 (en) * | 2012-04-12 | 2013-10-17 | Virgina Commonwealth University | A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS |
| SMT202200094T1 (it) * | 2013-12-24 | 2022-05-12 | Univ Virginia Commonwealth | Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta |
-
2017
- 2017-08-01 JP JP2019505256A patent/JP2019524774A/ja active Pending
- 2017-08-01 CN CN201780048064.0A patent/CN109862787A/zh active Pending
- 2017-08-01 KR KR1020197005444A patent/KR102568036B1/ko active Active
- 2017-08-01 TW TW106125933A patent/TW201818944A/zh unknown
- 2017-08-01 US US16/320,400 patent/US20190374554A1/en not_active Abandoned
- 2017-08-01 AU AU2017306140A patent/AU2017306140A1/en not_active Abandoned
- 2017-08-01 BR BR112019001193-5A patent/BR112019001193A2/pt not_active Application Discontinuation
- 2017-08-01 KR KR1020237027532A patent/KR20230124756A/ko not_active Withdrawn
- 2017-08-01 CA CA3031211A patent/CA3031211A1/en active Pending
- 2017-08-01 MX MX2019001324A patent/MX2019001324A/es unknown
- 2017-08-01 EP EP17837507.7A patent/EP3493671A4/en not_active Withdrawn
- 2017-08-01 WO PCT/US2017/044821 patent/WO2018026767A1/en not_active Ceased
- 2017-08-01 TW TW111139507A patent/TW202308651A/zh unknown
-
2019
- 2019-01-22 IL IL264389A patent/IL264389A/en unknown
-
2020
- 2020-10-16 US US17/072,994 patent/US20210169902A1/en not_active Abandoned
-
2021
- 2021-11-15 JP JP2021185644A patent/JP2022031733A/ja active Pending
-
2022
- 2022-07-13 AU AU2022205208A patent/AU2022205208A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102568036B1 (ko) | 2023-08-17 |
| AU2017306140A1 (en) | 2019-02-21 |
| AU2022205208A1 (en) | 2022-08-04 |
| CN109862787A (zh) | 2019-06-07 |
| WO2018026767A1 (en) | 2018-02-08 |
| EP3493671A1 (en) | 2019-06-12 |
| US20190374554A1 (en) | 2019-12-12 |
| CA3031211A1 (en) | 2018-02-08 |
| JP2019524774A (ja) | 2019-09-05 |
| EP3493671A4 (en) | 2020-04-08 |
| TW201818944A (zh) | 2018-06-01 |
| JP2022031733A (ja) | 2022-02-22 |
| KR20230124756A (ko) | 2023-08-25 |
| IL264389A (en) | 2019-02-28 |
| TW202308651A (zh) | 2023-03-01 |
| KR20190032530A (ko) | 2019-03-27 |
| BR112019001193A2 (pt) | 2019-04-30 |
| US20210169902A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001324A (es) | Uso de sulfatos de colesterol oxigenados (ocs) para el tratamiento de enfermedades inflamatorias de la piel y de lesiones de la piel. | |
| ZA202004764B (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| EP3229586A4 (en) | Genetically modified cells, tissues, and organs for treating disease | |
| MY194587A (en) | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration | |
| EP3645121B8 (en) | Methods for treating huntington's disease | |
| PH12016500840A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| MX2021000538A (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. | |
| MX389828B (es) | Usos de sulfatos de colesterol oxigenados (soc). | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| IL273169A (en) | A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases | |
| WO2014144932A3 (en) | Methods of using zscan4 for rejuvenating human cells | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| EP3746478A4 (en) | THERAPIES AND METHODS OF TREATING TLR2-MEDIATED DISEASES AND DISORDERS | |
| IL259710A (en) | Compositions and methods of treatment for mvid and related diseases | |
| SG11201804307WA (en) | Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same | |
| MX356814B (es) | Métodos y composiciones para neuroprotección. | |
| EA201792282A1 (ru) | Способы лечения заболеваний | |
| EA201990436A1 (ru) | Применение окисленных сульфатов холестерина (осх) для лечения воспалительных заболеваний кожи и кожных повреждений | |
| HK40096493A (zh) | Danon病和其它自噬障碍的治疗方法 | |
| EP3165226A4 (en) | Method for treating patients having cancerous skin diseases (variants) | |
| AU2016902338A0 (en) | Agents and methods for the diagnosis and treatment of disease | |
| HK40007580A (en) | Genetically modified cells, tissues, and organs for treating disease | |
| HK40009756A (en) | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions | |
| HK40040270A (en) | Therapies and methods to treat tlr2-mediated diseases and disorders | |
| PT3609486T (pt) | Sarpogrelato para uso num método para o tratamento de doença cardíaca em mamíferos |